Life Science Report is 100% dedicated to publicly traded biotech, pharma, medical, and health technology stocks. We reach the web's largest and most targeted niche of investors specifically focused on identifying new investment opportunities within the life sciences sector and its associated industries. Our flexible campaigns allow companies to rapidly launch broad market awareness programs as well as deploy targeted investor outreach strategies across a variety of mediums and outlets:
Jazz Pharmaceuticals to Acquire Chimerix, Further Diversifying Oncology Portfolio
Jazz Pharmaceuticals and Chimerix today announced the companies have entered into a definitive agreement for Jazz to acquire Chimerix for $8.55 per share in cash, representing a total consideration of approximately $935 million. The transaction has been approved... Read More
Gain full exposure across the entire Life Science Report platform through featured placement, branded news and stock quotes, banner rotation, featured profiles, video capsules, and much more.
